乙型肝炎病毒(HBV)再激活是指慢性HBV感染者合并肿瘤时接受细胞毒性或免疫抑制剂治疗期间出现的HBV复制, 可导致肝细胞连续性坏死及肝功能进行性下降,最终产生程度不一的损害,轻者表现为肝炎症状,重者出现暴发性肝功能衰竭。目前通常认为这是合并慢性HBV感染的肿瘤患者,尤其是非霍奇金淋巴瘤等接受化学疗法后常见的并发症。本研究旨在观察拉米夫定对这类患者HBV再激活的防治作用。 Hepatitis B virus (HBV) reactivation refers to HBV replication that occurs during cytotoxic or immunosuppressive therapy in patients with chronic HBV infection and results in progressive necrosis of hepatocytes and progressive loss of hepatic function, ultimately resulting in less A damage, the performance of light symptoms of hepatitis, severe cases of fulminant hepatic failure. At present, this is generally considered to be a common complication of chemotherapy in patients with chronic HBV infection, especially non-Hodgkin’s lymphoma. This study aimed to observe the prevention and treatment of lamivudine in such patients with HBV reactivation.